PREVADDUCT

Serial Number 88912457
606

Registration Progress

Application Filed
May 12, 2020
Under Examination
Nov 10, 2020
Approved for Publication
Sep 15, 2020
Published for Opposition
Sep 15, 2020
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: PREVADDUCT
Previous Owner: Adduct Pharmaceutical, Inc.
Classes: 005

Trademark Image

PREVADDUCT

Basic Information

Serial Number
88912457
Filing Date
May 12, 2020
Published for Opposition
September 15, 2020
Abandonment Date
December 18, 2023
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Dec 18, 2023
Classes
005

Rights Holder

Adduct Pharmaceutical, Inc.

03
Address
2711 South Loop Drive, Suite 4400
Ames, IA 50010

Ownership History

Adduct Pharmaceutical, Inc.

Original Applicant
03
Ames, IA

Adduct Pharmaceutical, Inc.

Owner at Publication
03
Ames, IA

Legal Representation

Attorney
Katherine Sullivan

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

31 events
Date Code Type Description Documents
Dec 18, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Dec 18, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
May 12, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 11, 2023 EX5G S SOU EXTENSION 5 GRANTED Loading...
May 7, 2023 EXT5 S SOU EXTENSION 5 FILED Loading...
May 11, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 7, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 12, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 10, 2022 EX4G S SOU EXTENSION 4 GRANTED Loading...
Nov 10, 2022 EXT4 S SOU EXTENSION 4 FILED Loading...
Nov 10, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 10, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 8, 2022 EX3G S SOU EXTENSION 3 GRANTED Loading...
May 8, 2022 EXT3 S SOU EXTENSION 3 FILED Loading...
May 8, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 9, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 5, 2021 EX2G S SOU EXTENSION 2 GRANTED Loading...
Nov 5, 2021 EXT2 S SOU EXTENSION 2 FILED Loading...
Nov 5, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 12, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 10, 2021 EX1G S SOU EXTENSION 1 GRANTED Loading...
May 10, 2021 EXT1 S SOU EXTENSION 1 FILED Loading...
May 10, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 10, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 15, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 15, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 26, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 11, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 9, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
May 26, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 15, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Dietary and nutritional supplements; Digestives for pharmaceutical purposes; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention of inflammation; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment and prevention of oxidative damage; Pharmaceutical preparations for the treatment and prevention of chronic inflammation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of chronic inflammation; Pharmaceutical preparations for the treatment of oxidative damage; Pharmaceutical preparations for the treatment of isoketal activity diseases and conditions; Pharmaceutical preparations for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, and immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating asthma; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for inflammation; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Anti-inflammatory preparations; Chemical preparations for pharmaceutical or medical purposes, namely, for oxidative damage, isoketal activity and chronic inflammation; Chemical preparations for pharmaceutical or medical purposes, namely, for diseases resulting from oxidative damage, isoketal activity or inflammation; Food supplements, namely, anti-oxidants; Medical preparations for the treatment of oxidative damage, isoketal activity and chronic inflammation; Medicinal preparations for inflammation; Pharmaceutical products and preparations to prevent swelling in the legs; Preparation for the relief of pain

Classification

International Classes
005